ArticleScientific reports2025
Optimized delivery of RNA silencing prolyl hydroxylase domain 2 for enhanced angiogenesis and osteogenesis using bioactive glass scaffolds.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the delivery of small interfering RNA (siRNA) silencing prolyl hydroxylase domain 2 (PHD2) via poly(lactic-co-glycolic acid) (PLGA)-bioactive glass scaffold to improve angiogenesis and osteogenesis for biomineralized tissue engineering. Polyethylenimine (PEI) was complexed with PHD2siRNA at 3:1, 6:1, and 8:1 ratios, and the resulting complexes were characterized by transmission electron microscopy, NanoSight analysis, and gel retardation assays. Their biological effects on human umbilical vein endothelial cells (HUVECs) were evaluated to determine the optimal ratio. PLGA-bioactive glass scaffolds were prepared and loaded with the most effective PEI/PHD2siRNA complex. HUVECs were used to confirm controlled RNA release from the scaffolds. The angiogenic effects of HUVECs and osteogenic differentiation of stem cells derived from human exfoliated deciduous teeth (SHED) were evaluated. The 8:1 ratio of PEI/PHD2siRNA demonstrated the highest efficiency, improving HUVEC tube formation. Incorporating these complexes into PLGA-bioactive glass scaffolds confirmed RNA release, as indicated by improved tube formation. The scaffolds promoted the proliferation and angiogenic differentiation of HUVECs. SHED cells cultured on the scaffolds demonstrated improved proliferation and osteogenic differentiation, evidenced by elevated alkaline phosphatase activity and mineral deposition. Coculturing SHED cells with HUVECs on the scaffolds exerted synergistic effects, producing more robust osteogenic differentiation than culturing SHED cells alone. Immunofluorescence staining revealed increased expression of both angiogenic and osteogenic markers. PHD2 siRNA delivery via PLGA-bioactive glass scaffolds enhanced angiogenesis and osteogenesis, supporting its potential in tissue engineering. This dual-function scaffold offers a promising strategy for dental and craniofacial regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.